Document Detail

Nitric oxide in critical respiratory failure of very low birth weight infants.
MedLine Citation:
PMID:  14980280     Owner:  NLM     Status:  MEDLINE    
Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator. In randomised trials, iNO increased gas exchange modestly and had no effect on the outcome (survival, chronic lung disease, CLD) in very low birth-weight (VLBW) infants. NO is an important component of the innate immune system and a lipid- soluble free radical scavenger that interacts with the surfactant system. VLBW infants with pneumonia and therapy-resistant, severe respiratory failure soon after birth were studied. Despite their infection, there was no detectable alveolar inducible NO synthase or nitrotyrosine, which is a toxic oxidation product of NO. These infants do not respond to exogenous surfactant and demonstrate severe pulmonary hypertension. However, they require exogenous surfactant prior to iNO. In most cases the disease is complicated by pneumonia and prolonged rupture of fetal membranes. We have shown evidence that iNO given within a few hours after birth reverses the progressive course of respiratory failure and pulmonary hypertension in VLBW infants.
Mikko Hallman; Outi Aikio
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Paediatric respiratory reviews     Volume:  5 Suppl A     ISSN:  1526-0542     ISO Abbreviation:  Paediatr Respir Rev     Publication Date:  2004  
Date Detail:
Created Date:  2004-02-24     Completed Date:  2004-05-10     Revised Date:  2009-10-14    
Medline Journal Info:
Nlm Unique ID:  100898941     Medline TA:  Paediatr Respir Rev     Country:  England    
Other Details:
Languages:  eng     Pagination:  S249-52     Citation Subset:  IM    
Department of Pediatrics and Biocenter Oulu, University of Oulu, Oulu, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Clinical Trials as Topic
Infant, Newborn
Infant, Very Low Birth Weight*
Nitric Oxide / physiology,  therapeutic use*
Pneumonia / drug therapy
Reg. No./Substance:
10102-43-9/Nitric Oxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Postnatal steroids and chronic lung disease in the newborn.
Next Document:  The molecular genetics of lung morphogenesis and injury repair.